Table 2.

Study schedule for patients participating from phase II

	Entry	Study period											Follow-up	Cessation
Visit	V1*	V2	V3	V4	V5	V6	V7	V8	V9	V10	V11	V12	V13	–
Timing (D=day, W=week)	D0	D1	D2	D4	W1	W2	W3	W4	W6	W8	W10	W12	W16	–
Entry
Informed consent	○
Eligibility screen	○	○
Registration		○
Assessments
Vital signs	○	○	○	○	○	○	○	○	○	○	○	○	○	○
Height, weight and head circumference	○							○		○			○	○
Slit-lamp examination	○	○	○	○	○	○	○	○	○	○	○	○	○	○
Fundus examination	○	○			○		○	○	○	○	○	○	○	○
Fundus camera	○											○	○	○
CBC/blood chemistry test	○												○	○
Pharmacokinetics†		○	○	○	○	○	○	○	○	○	○
Urinalysis	○				○			○					○	○
Imaging evaluation of the CNS	○												○	○
AEs and ADRs		○	○	○	○	○	○	○	○	○	○	○	○	○

*V1 and V2 can be performed on the same day.

†Blood samples for pharmacokinetic studies will be collected 3 times at any point during the study period. Blood will be drawn at any point up to 4 hours after ripasudil administration.

ADR, adverse drug reaction; AE, adverse event; CBC, complete blood cell count; CNS, central nervous system.